All News
Filter News
Found 7,637 articles
-
Sandoz’s two interchangeable biosimilars, Jubbonti and Xgeva, are poised to challenge Amgen’s blockbuster bone drug denosumab. However, no launch details were announced Tuesday due to ongoing patent litigation.
-
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
3/6/2024
Kamada Ltd. announced financial results for the three months and year ended December 31, 2023.
-
Kamada Issues 2024 CEO Letter to Shareholders
3/6/2024
Kamada Ltd., a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, issued a Letter to Shareholders from Amir London, Chief Executive Officer.
-
Amgen Announces 2024 Second Quarter Dividend
3/6/2024
Amgen announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024.
-
Sandoz receives FDA approval for first and only denosumab biosimilars
3/5/2024
Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) approved Wyost® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz), the first and only FDA-approved denosumab biosimilars, to treat all indications of the reference medicines.
-
Sandoz announces nominations to the Board of Directors and leadership change
3/5/2024
The Board of Directors of Sandoz announced that it proposes Mathai Mammen, M.D., Ph.D., and Michael Rechsteiner for election to its Board of Directors at the company’s Annual General Meeting on April 30, 2024.
-
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
3/5/2024
Innovent Biologics, Inc. and AnHeart Therapeutics announce that the Center for Drug Evaluation of China's National Medical Products Administration has accepted a second New Drug Application for taletrectinib adipate capsule, a next-generation ROS1 tyrosine kinase inhibitor.
-
FDA Roundup: March 5, 2024
3/5/2024
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.
-
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
3/5/2024
Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced that it will release financial results for the full year 2023, after U.S. markets close on Wednesday, March 20, 2024.
-
Phenomenex Introduces Biozen dSEC-7, A New Way to Study AAVs with Unprecedented Speed and Efficiency
3/5/2024
Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, proudly announces its newest Size Exclusion Chromatography product, Biozen dSEC-7, for the analysis of AAVs.
-
Revance Announces Proposed Public Offering of Common Stock - March 04, 2024
3/4/2024
Revance Therapeutics, Inc. announced a proposed underwritten public offering of $100 million of its common stock.
-
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
3/4/2024
Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock.
-
ANEW MEDICAL Announces Key Patent Issued in China to Protect Klotho Protein and Gene Delivery Systems
3/4/2024
ANEW MEDICAL, INC. announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW's Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases.
-
JAMP Pharma Group Acquires a Pharmaceutical Manufacturing Facility in Lévis, Quebec
2/29/2024
JAMP Pharma Group, a leading company in the Canadian pharmaceutical industry for over 35 years, announces subject to Superior Court approval and the fulfillment of customary closing conditions, the acquisition of the assets of Pharmalab's manufacturing facility in Lévis, which ceased operations in August 2023.
-
Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®
2/29/2024
Biocon Biologics Ltd (BBL) announced today that the Company has signed a settlement and license agreement with Janssen Biotech Inc., and Johnson & Johnson (collectively known as Janssen) that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara®, in the United States of America.
-
Alvotech Appoints Interim Chief Quality Officer
2/29/2024
Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced that Christina Siniscalchi will join its corporate leadership team as interim Chief Quality Officer.
-
This week Lori, Greg and Tyler discuss AbbVie: how longtime CEO Richard Gonzalez navigated Humira's LOE, his victorious retirement announcement, and the future of biosimilars.
-
Plus, last week Richard Gonzalez announced his retirement from AbbVie, PhRMA appointed Gilead’s O’Day to chair its board and Joseph Papa became president and CEO of Emergent.
-
UCB on Growth Path for a Decade Plus
2/28/2024
Our 2023 performance showcases our unwavering commitment to ensuring people with severe diseases can live the life they like, as free as possible from challenges of disease, reaching more than 3.2 million patients globally with severe immunological and neurological conditions.
-
Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024Company to Host Conference Call at 8:30am ET
2/28/2024
Kamada Ltd. announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2023, as well as provide 2024 financial guidance, prior to the open of the U.S. financial markets on Wednesday, March 6, 2024.